1. Home
  2. ADPT vs CLM Comparison

ADPT vs CLM Comparison

Compare ADPT & CLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

N/A

Current Price

$12.44

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Logo Cornerstone Strategic Value Fund Inc. New

CLM

Cornerstone Strategic Value Fund Inc. New

N/A

Current Price

$7.46

Market Cap

2.3B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ADPT
CLM
Founded
2009
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.3B
IPO Year
2019
1995

Fundamental Metrics

Financial Performance
Metric
ADPT
CLM
Price
$12.44
$7.46
Analyst Decision
Strong Buy
Analyst Count
9
0
Target Price
$17.78
N/A
AVG Volume (30 Days)
1.5M
2.7M
Earning Date
05-05-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
63.89
N/A
EPS
N/A
N/A
Revenue
$276,976,000.00
N/A
Revenue This Year
$3.98
N/A
Revenue Next Year
$22.72
N/A
P/E Ratio
N/A
N/A
Revenue Growth
54.77
N/A
52 Week Low
$6.68
$6.57
52 Week High
$20.76
$8.53

Technical Indicators

Market Signals
Indicator
ADPT
CLM
Relative Strength Index (RSI) 24.22 38.40
Support Level $12.32 $7.05
Resistance Level $13.45 $8.29
Average True Range (ATR) 0.83 0.17
MACD -0.26 0.00
Stochastic Oscillator 10.61 25.00

Price Performance

Historical Comparison
ADPT
CLM

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About CLM Cornerstone Strategic Value Fund Inc. New

Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, industrials, utilities, energy, telecommunication services, materials, and other sectors.

Share on Social Networks: